Cargando…
Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
PURPOSE: To evaluate the clinical outcomes of lenvatinib plus PD-1 inhibitors (LP) and regorafenib (R) in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure. METHODS: From June 2018 to September 2021, 68 patients from a single center who received lenvatinib combined with P...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612499/ https://www.ncbi.nlm.nih.gov/pubmed/37899984 http://dx.doi.org/10.2147/TCRM.S420371 |
_version_ | 1785128714453909504 |
---|---|
author | Xu, Yongkang Fu, Shumin Liu, Kan Mao, Ye Wu, Jianbing |
author_facet | Xu, Yongkang Fu, Shumin Liu, Kan Mao, Ye Wu, Jianbing |
author_sort | Xu, Yongkang |
collection | PubMed |
description | PURPOSE: To evaluate the clinical outcomes of lenvatinib plus PD-1 inhibitors (LP) and regorafenib (R) in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure. METHODS: From June 2018 to September 2021, 68 patients from a single center who received lenvatinib combined with PD-1 inhibitors or regorafenib after sorafenib treatment failure were analyzed. The tumor response and survival outcomes were compared between the LP group and R group. Prognostic factors for OS and PFS were determined using Cox proportional hazard regression models. RESULTS: The ORR increased in the LP group (19.5% vs 7.4%, p =0.294), and the DCR was better in the R group (73.2% vs 44.4%, p =0.017). Additionally, median PFS and OS were not significantly different between the LP group and R two groups in survival analysis (PFS: 5.3 months vs 3.0 months, p =0.633; OS: 11.8 months vs 8.0 months, p =0.699). The common adverse events (≥grade 3) were hand-foot skin reactions (13.1%). In multivariate analyses, AFP≥400 ng/mL and ECOG PS 2 were independent risk factors for poor prognosis. CONCLUSION: The LP group appeared to have a trend of greater tumor response and a higher disease control rate than the R group among patients with sorafenib-resistant HCC, although PFS and OS did not differ significantly between the two groups. |
format | Online Article Text |
id | pubmed-10612499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-106124992023-10-29 Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study Xu, Yongkang Fu, Shumin Liu, Kan Mao, Ye Wu, Jianbing Ther Clin Risk Manag Original Research PURPOSE: To evaluate the clinical outcomes of lenvatinib plus PD-1 inhibitors (LP) and regorafenib (R) in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure. METHODS: From June 2018 to September 2021, 68 patients from a single center who received lenvatinib combined with PD-1 inhibitors or regorafenib after sorafenib treatment failure were analyzed. The tumor response and survival outcomes were compared between the LP group and R group. Prognostic factors for OS and PFS were determined using Cox proportional hazard regression models. RESULTS: The ORR increased in the LP group (19.5% vs 7.4%, p =0.294), and the DCR was better in the R group (73.2% vs 44.4%, p =0.017). Additionally, median PFS and OS were not significantly different between the LP group and R two groups in survival analysis (PFS: 5.3 months vs 3.0 months, p =0.633; OS: 11.8 months vs 8.0 months, p =0.699). The common adverse events (≥grade 3) were hand-foot skin reactions (13.1%). In multivariate analyses, AFP≥400 ng/mL and ECOG PS 2 were independent risk factors for poor prognosis. CONCLUSION: The LP group appeared to have a trend of greater tumor response and a higher disease control rate than the R group among patients with sorafenib-resistant HCC, although PFS and OS did not differ significantly between the two groups. Dove 2023-10-24 /pmc/articles/PMC10612499/ /pubmed/37899984 http://dx.doi.org/10.2147/TCRM.S420371 Text en © 2023 Xu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Xu, Yongkang Fu, Shumin Liu, Kan Mao, Ye Wu, Jianbing Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study |
title | Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study |
title_full | Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study |
title_fullStr | Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study |
title_full_unstemmed | Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study |
title_short | Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study |
title_sort | lenvatinib plus pd-1 inhibitors versus regorafenib in patients with advanced hepatocellular carcinoma after the failure of sorafenib: a retrospective study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612499/ https://www.ncbi.nlm.nih.gov/pubmed/37899984 http://dx.doi.org/10.2147/TCRM.S420371 |
work_keys_str_mv | AT xuyongkang lenvatinibpluspd1inhibitorsversusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterthefailureofsorafenibaretrospectivestudy AT fushumin lenvatinibpluspd1inhibitorsversusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterthefailureofsorafenibaretrospectivestudy AT liukan lenvatinibpluspd1inhibitorsversusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterthefailureofsorafenibaretrospectivestudy AT maoye lenvatinibpluspd1inhibitorsversusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterthefailureofsorafenibaretrospectivestudy AT wujianbing lenvatinibpluspd1inhibitorsversusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterthefailureofsorafenibaretrospectivestudy |